|
|
Article: Biotech's big bazaar.(survey of the products offered by Genentech, Amgen, and other companies in the biotechnology industry)
- Article from:
- U.S. News & World Report
- Article date:
- January 21, 2002
- Author:
CopyrightCOPYRIGHT 2002 All rights reserved. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biotech investors place their bets along a continuum of risk. Profitable blue chips are less dicey, as are drug company stocks with biotech exposure. The greater risks--and potentially greater rewards--come from up-and-comers on the verge of their first big product. Investors who swing for the fences may consider early-stage firms with cutting-edge technology.
The Blue Chips
Come this spring, Miya Weber, 48, expects to welcome her seventh grandchild into the world. If it hadn't been for the biotechnology drug Rituxan, the juvenile probation officer in Roseville, Calif., probably would never know this baby or any of her other grandchildren. Lymphoma ...